Madrigal Pharmaceuticals Inc (MDGL) Stock Price & News

MDGL:NASDAQ

Madrigal Pharmaceuticals Inc

$427.39

+0.51%

(+2.18) 1D

$425.72

-0.39% (-1.67)

After hours

Closed: Nov 13, 4:00:01 PM GMT-5 · USD

All symbols

	Symbol	Price	Change	% Change

Generating top insights for MDGL...

Open

$424.92

High

$428.90

Low

$414.16

Mkt. cap

9.93B

Avg. vol.

492.20K

Volume

441.25K

52-wk high

$615.00

52-wk low

$353.54

EPS

-$5.96

Beta

-0.98

Shares outstanding

23.23M

No. of employees

915

Open

$424.92

High

$428.90

Low

$414.16

Mkt. cap

9.93B

Avg. vol.

492.20K

Volume

441.25K

52-wk high

$615.00

52-wk low

$353.54

EPS

-$5.96

Beta

-0.98

Shares outstanding

23.23M

No. of employees

915

Related stocks

SMMT

Summit Therapeutics Inc

Revolution Medicines Inc

$172.29

-2.30%

VKTX

Viking Therapeutics Inc

$29.22

+5.95%

News stories

From web sources and news partners

FinancialContent

1 day ago

Kaplan Fox Reminds Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) of an Ongoing Investigation Into Potential Securities Law Violations

Morningstar

2 days ago

Investigation of MDGL Reminder: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP

About Madrigal Pharmaceuticals Inc

CEOPaul A. Friedman

Employees915

Founded2011

HeadquartersWest Conshohocken, Pennsylvania, United States

SectorHealth Care

IndustryBiotechnology

Websitemadrigalpharma.com

Analyst	Recommendation	Action	Price target	Projected	Date
Ananda Ghosh H.C. Wainwright	Buy	Reiterated	$620.00	+45.1%	11/12/2026
Jason Zemansky Bank of America Securities	Hold	Maintained	$479.00	+12.1%	11/09/2026
Srikripa Devarakonda Truist Financial	Buy	Maintained	$743.00	+73.8%	11/04/2026
Sadia Rahman Wells Fargo	Buy	Reiterated	$685.00	+60.3%	11/04/2026
Edward Nash Canaccord Genuity	Buy	Reiterated	$633.00	+48.1%	11/04/2026
Eliana Merle Barclays	Buy	Maintained	$962.00	+125.1%	11/04/2026
Eric Joseph Citi	Buy	Maintained	$760.00	+77.8%	11/04/2026
Unknown Analyst B. Riley Securities	Buy	Reiterated	$670.00	+56.8%	10/29/2026
Ashwani Verma UBS	Buy	Maintained	$735.00	+72%	10/15/2026
Andrew Fein H.C. Wainwright	Buy	Reiterated	$620.00	+45.1%	10/08/2026
Andrea Newkirk Goldman Sachs	Buy	Initiated	$704.00	+64.7%	09/24/2026
Andy Chen Wolfe Research	Buy	Upgraded	$605.00	+41.6%	08/04/2026
Ritu Baral TD Cowen	Buy	Maintained	$644.00	+50.7%	07/30/2026
Unknown Analyst UBS	Buy	Maintained	$669.00	+56.5%	07/21/2026
Jonathan Wolleben Citizens JMP	Buy	Maintained	$739.00	+72.9%	07/17/2026
Unknown Analyst Jefferies	Buy	Maintained	$600.00	+40.4%	06/30/2026
Yasmeen Rahimi Piper Sandler	Buy	Maintained	$900.00	+110.6%	06/29/2026
Michael DiFiore Evercore ISI	Buy	Maintained	$649.00	+51.9%	05/07/2026
Kaveri Pohlman Clear Street	Buy	Maintained	$680.00	+59.1%	05/06/2026
Jay Olson Oppenheimer	Buy	Maintained	$650.00	+52.1%	02/09/2026

All values in USD	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Revenue	321.08M	311.34M	364.25M	431.27M
Cost of goods sold	24.45M	26.85M	40.01M	37.82M
Cost of revenue	24.45M	26.85M	40.01M	37.82M
Research and development expenses	116.27M	108.69M	91.18M	71.76M
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	239.98M	268.52M	289.38M	265.71M
Operating expense	356.24M	377.21M	380.55M	337.46M
Total operating expenses	380.69M	404.06M	420.56M	375.28M
Operating income	-59.61M	-92.72M	-56.31M	55.99M
Other non operating income	-128.00K	-	-	-
EBT including unusual items	-58.58M	-94.39M	-57.94M	55.44M
EBT excluding unusual items	-58.58M	-94.39M	-57.94M	55.44M
Income tax expense	-	-	-	-
Effective tax rate	-	-	-	-
Other operating expenses	-	-	-	-
Net income	-58.58M	-94.39M	-57.94M	55.44M
Net profit margin	-18.24%	-30.32%	-15.91%	12.86%
Earnings per share	-2.57	-1.38	-1.99	-
Interest and investment income	9.46M	8.24M	7.10M	8.24M
Interest expense	-8.30M	-7.82M	-7.94M	-8.07M
Net interest expenses	1.16M	424.00K	-836.00K	170.00K
Depreciation and amortization charges	-	-	-	-
EBITDA	-59.22M	-92.34M	-55.93M	56.38M
Gain or loss from assets sale	-	-	-	-

Finance

Ask anything